Zoetis Inc. (NYSE:ZTS) is one of the Best Wide Moat Stocks to Buy According to Wall Street Analysts. On May 18, Citi reduced its price objective on the company’s stock to $112 from $145 and kept a “Buy” rating on the shares. Notably, the firm reduced Zoetis Inc. (NYSE:ZTS)’s estimates after the difficult report for Q1 2026. However, the analyst believes that the company has a premium portfolio when the consumers are trading downwards.
The company saw revenue of $2.3 billion in Q1 2026, implying an increase of 3% YoY and flat on an organic operational basis. The revenue in the U.S. segment amounted to $1.1 billion, demonstrating a decline of 8% on a reported and organic operational basis compared to Q1 2025, with companion animal product sales falling 11% because of softer end-market demand and competitive landscape.
For FY 2026, Zoetis Inc. (NYSE:ZTS) expects revenue of between $9.680 billion – $9.960 billion (organic operational growth of 2% – 5%), while adjusted net income is anticipated between $2.870 billion and $2.950 billion (organic operational growth of 2% – 6%).
Zoetis Inc. (NYSE:ZTS) is a leading animal health company, and it discovers, develops, manufactures, and commercializes vaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock.
While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.
Disclosure: None. Follow Insider Monkey on Google News.